| NCT06930573 A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk | Phase 4 | Recruiting | 30 (est.) | May 24, 2026 (est.) | No |
| NCT06953999 A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | Phase 3 | Recruiting | 999 (est.) | May 14, 2027 (est.) | No |
| HARMONi-GI3 · NCT07228832 Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Phase 3 | Recruiting | 900 (est.) | May 31, 2028 (est.) | No |
| HARMONi-GU1 · NCT07815665 A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma | Phase 2/3 | Recruiting | 800 (est.) | Oct 31, 2030 (est.) | No |
| ILLUMINE · NCT07264075 Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN | Phase 3 | Recruiting | 780 (est.) | May 2030 (est.) | No |
| NCT06591520 AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer | Phase 3 | Active, not recruiting | 682 | Oct 2026 (est.) | No |
| NCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | Phase 3 | Recruiting | 560 (est.) | Jan 13, 2027 (est.) | No |
| NCT06601335 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Phase 3 | Recruiting | 510 (est.) | Jan 2027 (est.) | No |
| NCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | Phase 3 | Recruiting | 416 (est.) | Dec 2026 (est.) | No |
| NCT07765433 Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer | Phase 2/3 | Not yet recruiting | 336 (est.) | Dec 31, 2028 (est.) | No |
| I-SPY · NCT01042379 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | Recruiting | 5,000 (est.) | Dec 2030 (est.) | No |
| FASCINATE-N · NCT05582499 Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | Phase 2 | Recruiting | 716 (est.) | Dec 31, 2027 (est.) | No |
| NCT06877650 First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors | Phase 1/2 | Recruiting | 436 (est.) | Mar 30, 2028 (est.) | No |
| NCT06683846 Ivonescimab in the Treatment of Multiple Advanced Tumors | Phase 2 | Recruiting | 400 (est.) | Nov 30, 2027 (est.) | No |
| NCT07560124 A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer | Phase 1/2 | Not yet recruiting | 286 (est.) | Jun 6, 2028 (est.) | No |
| NCT06530251 A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | Phase 1/2 | Recruiting | 280 (est.) | Jun 2026 (est.) | No |
| NCT05382442 A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase 2 | Active, not recruiting | 254 (est.) | May 15, 2026 (est.) | No |
| NCT05951608 A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors | Phase 1/2 | Active, not recruiting | 216 (est.) | May 1, 2026 (est.) | No |
| NCT07070479 Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | Phase 2 | Recruiting | 208 (est.) | Jan 30, 2027 (est.) | No |
| NCT07591090 A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer | Phase 2 | Recruiting | 200 (est.) | Sep 1, 2027 (est.) | No |
| NCT06560112 An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer | Phase 2 | Recruiting | 172 (est.) | May 1, 2026 (est.) | No |
| NCT05846867 A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer | Phase 1/2 | Active, not recruiting | 170 (est.) | May 8, 2026 (est.) | No |
| NCT06790212 Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer | Phase 2 | Not yet recruiting | 168 (est.) | Aug 30, 2027 (est.) | No |
| NCT07114315 A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer | Phase 2 | Recruiting | 160 (est.) | Aug 2027 (est.) | No |
| NCT05214482 A Study of AK112 in Advanced Malignant Tumors | Phase 1/2 | Completed | 154 | Nov 20, 2025 | No |
| NCT05229497 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | Phase 1/2 | Active, not recruiting | 154 (est.) | Dec 31, 2026 (est.) | No |
| Huaxi · NCT07374250 Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma | Phase 2 | Not yet recruiting | 154 (est.) | Dec 31, 2027 (est.) | No |
| NCT06686030 Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | Phase 2 | Recruiting | 150 (est.) | Oct 2027 (est.) | No |
| NCT07857135 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | Phase 1/2 | Not yet recruiting | 140 (est.) | Feb 3, 2029 (est.) | No |
| NCT06938321 A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer | Phase 1/2 | Recruiting | 135 (est.) | May 2027 (est.) | No |
| NCT07636772 A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma | Phase 2 | Not yet recruiting | 132 (est.) | Aug 24, 2028 (est.) | No |
| NCT07021950 AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | 130 (est.) | Oct 31, 2027 (est.) | No |
| COLIBRI-GI · NCT07359456 Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases | Phase 2 | Not yet recruiting | 130 (est.) | Aug 2029 (est.) | No |
| NCT07394218 ctDNA-guided Treatment Decision-making | Phase 2 | Recruiting | 122 (est.) | Mar 31, 2028 (est.) | No |
| NCT05227664 A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | Phase 2 | Active, not recruiting | 120 (est.) | Dec 30, 2026 (est.) | No |
| NCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Phase 1/2 | Active, not recruiting | 110 (est.) | Dec 30, 2026 (est.) | No |
| NCT06904300 Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer | Phase 2 | Not yet recruiting | 110 (est.) | Apr 30, 2028 (est.) | No |
| NeoASPECT · NCT07743632 Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC | Phase 2 | Not yet recruiting | 110 (est.) | Dec 2032 (est.) | No |
| TRIUNITE-03 · NCT06718543 Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer | Phase 2 | Recruiting | 100 (est.) | Oct 31, 2026 (est.) | No |
| NCT07052253 A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | Phase 2 | Recruiting | 100 (est.) | May 10, 2027 (est.) | No |
| SMT112-216 · NCT07877194 A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer | Phase 2 | Not yet recruiting | 100 (est.) | Apr 12, 2029 (est.) | No |
| NCT06444009 A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | 90 (est.) | Dec 1, 2025 (est.) | No |
| NCT06919510 A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer | Phase 2 | Not yet recruiting | 90 (est.) | Jun 1, 2026 (est.) | No |
| NCT06959550 Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer | Phase 2 | Recruiting | 90 (est.) | Jul 1, 2028 (est.) | No |
| NCT07381075 A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | 90 (est.) | Dec 31, 2028 (est.) | No |
| GRACIE · NCT06846346 Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | 88 (est.) | Sep 2027 (est.) | No |
| NCT05689853 Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | Phase 1/2 | Recruiting | 87 (est.) | Dec 2026 (est.) | No |
| NCT07854600 A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer | Phase 2 | Recruiting | 87 (est.) | Oct 2028 (est.) | No |
| NCT06814067 Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | 80 (est.) | Feb 10, 2029 (est.) | No |
| NCT07885319 Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma | Phase 1/2 | Recruiting | 78 (est.) | Nov 30, 2028 (est.) | No |
| SEVILLA · NCT06529718 Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients | Phase 2 | Recruiting | 72 (est.) | Aug 3, 2027 (est.) | No |
| NCT07357220 A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases | Phase 1/2 | Not yet recruiting | 72 (est.) | Feb 28, 2027 (est.) | No |
| NCT07091227 Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma | Phase 2 | Not yet recruiting | 66 (est.) | Jul 20, 2026 (est.) | No |
| NCT07095803 Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure | Phase 2 | Not yet recruiting | 60 (est.) | Feb 1, 2026 (est.) | No |
| NCT07488572 Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | Phase 2 | Enrolling by invitation | 60 (est.) | Jun 1, 2027 (est.) | No |
| NCT04597541 A Study of AK112 for Advanced Solid Tumors | Phase 1/2 | Completed | 59 | Mar 31, 2022 | No |
| NCT06814158 Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer | Phase 2 | Not yet recruiting | 57 (est.) | Jul 30, 2026 (est.) | No |
| NCT07712094 AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer | Phase 2 | Not yet recruiting | 56 (est.) | Feb 27, 2029 (est.) | No |
| NCT07103447 Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC | Phase 2 | Not yet recruiting | 54 (est.) | Dec 31, 2027 (est.) | No |
| NCT04870177 Study of AK112 in the Treatment of Advanced Gynecological Tumors | Phase 2 | Completed | 53 | May 10, 2024 | No |
| NCT06977542 Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | 53 (est.) | Jan 2029 (est.) | No |
| NCT07647016 Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study | Phase 2 | Recruiting | 53 (est.) | Dec 30, 2027 (est.) | No |
| NCT06196697 AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer | Phase 2 | Recruiting | 50 (est.) | Jan 2027 (est.) | No |
| NCT06402435 SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer | Phase 2 | Recruiting | 50 (est.) | Aug 31, 2026 (est.) | No |
| NCT06925724 A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Phase 2 | Recruiting | 50 (est.) | Apr 2027 (est.) | No |
| NCT07244978 Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | 49 (est.) | Dec 31, 2027 (est.) | No |
| NCT07064902 Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | 48 (est.) | Aug 31, 2026 (est.) | No |
| NCT06791148 Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer | Phase 2 | Recruiting | 45 (est.) | Jul 10, 2027 (est.) | No |
| NCT06802666 Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer | Phase 2 | Recruiting | 45 (est.) | Sep 1, 2026 (est.) | No |
| NCT07385001 A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC | Phase 1/2 | Recruiting | 45 (est.) | Jan 28, 2027 (est.) | No |
| NCT07809893 Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients | Phase 2 | Recruiting | 45 (est.) | Dec 31, 2027 (est.) | No |
| ANTHELA · NCT07917481 A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | 44 (est.) | Jun 2029 (est.) | No |
| NCT07244965 Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | 42 (est.) | Jul 1, 2027 (est.) | No |
| AK112 · NCT07565389 Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | 42 (est.) | May 2031 (est.) | No |
| NCT05432492 A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC) | Phase 2 | Completed | 40 | Apr 30, 2025 | No |
| NCT06760520 Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer | Phase 2 | Not yet recruiting | 40 (est.) | Dec 20, 2027 (est.) | No |
| NCT06848842 Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases | Phase 2 | Recruiting | 40 (est.) | Jun 2027 (est.) | No |
| NCT06940518 Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | 40 (est.) | Jan 19, 2028 (est.) | No |
| NCT07070466 Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | Phase 2 | Recruiting | 40 (est.) | Dec 1, 2026 (est.) | No |
| NCT06145308 Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | Phase 2 | Recruiting | 39 (est.) | Jul 10, 2028 (est.) | No |
| BALISTA · NCT06793332 BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | Phase 2 | Recruiting | 39 (est.) | Dec 31, 2026 (est.) | No |
| Bi-MAPS · NCT06840834 Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy | Phase 2 | Recruiting | 38 (est.) | Sep 30, 2026 (est.) | No |
| NCT06844422 Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) | Phase 1/2 | Recruiting | 37 (est.) | Feb 18, 2028 (est.) | No |
| NCT07188103 Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | 37 (est.) | Jun 30, 2027 (est.) | No |
| NCT06196775 A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | 36 (est.) | Jan 31, 2026 (est.) | No |
| NCT06491472 Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer | Phase 2 | Recruiting | 36 (est.) | Jul 15, 2026 (est.) | No |
| NCT06537011 AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | 36 (est.) | Jul 15, 2027 (est.) | No |
| NCT06593548 Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer | Phase 2 | Unknown status | 36 (est.) | Nov 1, 2026 (est.) | No |
| I-MAC · NCT06805617 A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers | Phase 2 | Recruiting | 35 (est.) | Jul 1, 2027 (est.) | No |
| NCT07017673 Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | Phase 2 | Recruiting | 34 (est.) | Dec 2027 (est.) | No |
| NCT07226544 Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer | Phase 2 | Recruiting | 31 (est.) | Dec 5, 2028 (est.) | No |
| NCT06375486 Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma(uHCC). | Phase 2 | Unknown status | 30 (est.) | Mar 14, 2025 (est.) | No |
| NCT06472895 A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma | Phase 1/2 | Not yet recruiting | 30 (est.) | Dec 20, 2025 (est.) | No |
| NCT06489197 AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients | Phase 2 | Recruiting | 30 (est.) | Oct 30, 2026 (est.) | No |
| NCT06944106 A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer | Phase 2 | Recruiting | 30 (est.) | Apr 28, 2026 (est.) | No |
| DIVON · NCT06957561 Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | Phase 1/2 | Not yet recruiting | 30 (est.) | May 1, 2026 (est.) | No |
| NCT06993025 Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies | Phase 2 | Not yet recruiting | 30 (est.) | Apr 25, 2026 (est.) | No |
| STAR · NCT07162714 SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer | Phase 2 | Recruiting | 30 (est.) | Mar 31, 2027 (est.) | No |
| NCT07753824 A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | Phase 2 | Not yet recruiting | 30 (est.) | Nov 28, 2031 (est.) | No |
| NCT06991491 Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004) | Phase 2 | Not yet recruiting | 29 (est.) | Jun 30, 2026 (est.) | No |
| NCT07229417 A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma | Phase 2 | Recruiting | 29 (est.) | Sep 30, 2027 (est.) | No |
| SENIOR-HN · NCT07094685 Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer | Phase 2 | Recruiting | 28 (est.) | Aug 1, 2027 (est.) | No |
| NCT06980077 Ivonescimab for the Treatment of Thymic Cancer | Phase 2 | Recruiting | 25 (est.) | Jun 17, 2027 (est.) | No |
| NCT06567314 Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | 24 (est.) | Sep 1, 2028 (est.) | No |
| iTHYM · NCT06750952 Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial | Phase 2 | Not yet recruiting | 24 (est.) | Dec 20, 2026 (est.) | No |
| ICORE-GBC · NCT07767994 AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer | Phase 2 | Not yet recruiting | 22 (est.) | Jun 30, 2028 (est.) | No |
| NCT07130240 Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer | Phase 2 | Recruiting | 20 (est.) | Aug 31, 2028 (est.) | No |
| NCT07743138 STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) | Phase 2 | Not yet recruiting | 20 (est.) | May 1, 2028 (est.) | No |
| NCT04999605 A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer Why stopped (registry): Too low inclusion rate | Phase 1/2 | Terminated | 8 | Jun 10, 2022 | No |